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Abstract
Summary In this prospective study, 87 children were
followed up from birth to 14 months with data on maternal
vitamin D status during the pregnancy. Postnatal vitamin D
supplementation improved vitamin D status but only partly
eliminated the differences in bone variables induced by
maternal vitamin D status during the fetal period.
Introduction Intrauterine nutritional deficits may have
permanent consequences despite improved nutritional status
postnatally. We evaluated the role of prenatal and postnatal
vitamin D status on bone parameters in early infancy.
Methods Eighty-seven children were followed from birth to
14 months. Background data were collected with a
questionnaire and a 3-day food record. At 14 months bone
variables were measured with peripheral computed tomog-
raphy (pQCT) from the left tibia. Serum 25-OHD and bone
turnover markers were determined. Findings were com-
pared with maternal vitamin D status during pregnancy.
Results The children were divided into two groups based
on vitamin D status during pregnancy. Despite discrepant
S-25-OHD at baseline (median 36.3 vs. 52.5 nmol/l, p<
0.001), the values at 14 months were similar (63 vs.
66 nmol/l, p=0.58) in Low D and High D. Serum 25-OHD
increased more in Low D (p<0.001) despite similar total
intake of vitamin D (mean 12.3 μg/day). In Low D, tibial
bone mineral content (BMC) was lower at birth but BMC
gain was greater (multivariate analysis of variance [MAN-
OVA]; p=0.032) resulting in similar BMC at 14 months in
the two groups. In High D, tibial total bone cross-sectional
area was higher at baseline; the difference persisted at
14 months (MANOVA; p=0.068). Bone mineral density
(BMD) and ΔBMD were similar in the two groups.
Conclusions Postnatal vitamin D supplementation improved
vitamin D status but only partly eliminated the differences in
bone variables induced by maternal vitamin D status during
the fetal period. Further attention should be paid to improving
vitamin D status during pregnancy.
Keywords Bone growth.Development.Maternal vitamin
D status.Pediatric.Vitamin D
Introduction
Poor growth during the fetal period, infancy and early child-
hood is associated with lower adult bone mass and increased
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DOI 10.1007/s00198-010-1499-4fracture risk later in life [1–3]. During the fetal period, it is
likely that metabolic and endocrine systems are programmed
to allow the fetus to adapt to the in utero environment [4].
Vitamin D is a seco sterol that modifies various biological
functions in the body [5], and researchers have identified 37
target organs for vitamin D [5]. Low maternal vitamin D
status or inadequate dietary vitamin D intake during
pregnancy predisposes children to asthma and allergic
rhinitis [6], diabetes [7], acute lower respiratory infection
[8], and impaired bone mass accrual. This is evidenced by
smaller bone cross-sectional area (CSA) and bone mineral
content (BMC) at birth [9, 10] and at 9 years of age [11].
Programming of skeletal growth may occur through
growth hormone—IGF-I axis [4, 12], whereas bone quality
may be determined by factors related to differentiation of
mesenchymal stem cells [13, 14]. The intrauterine environ-
ment strongly affects growth rate in infancy, but may also
influence growth in puberty [15]. The extent to which
changes in nutrient supply between intrauterine and
postnatal periods affect growth and development, per se,
has not been well established [4]. The most critical views
predict that intrauterine nutritional deficits have permanent
consequences and that a newborn’s metabolism may not
adapt to improved nutritional status; the nutrients may not
be utilized efficiently and the risk for disease may be
maintained despite improved nutritional status [16].
However, postnatal catch-up occurs in linear growth if
the fetal deprivation and its timing and magnitude have
not been too critical [17].
Previously the authors of the current study have reported
that during the pregnancy, 69% of the women and 37% of
the newborns at birth were vitamin D deficient (defined in
women as S-25-OHD <50 nmol/l [18, 19] and in the
newborn as <37.5 nmol/l [20]). The newborn bone
variables were measured with peripheral quantitative
computed tomography (pQCT) during the hospital stay.
Based on these results, it was concluded that maternal
vitamin D status affects bone mineral accrual and influences
bone size during the intrauterine period [10].
The present prospective study had two objectives. The
first was to follow whether the vitamin D-associated
skeletal effects observed at birth persist during the first
year of life, and the second was to evaluate the impact of
postnatal vitamin D status on bone growth and develop-
ment in early infancy.
Subjects and methods
Families (N=124) were initially recruited and assessed
between October and December 2007 during their labor
visit to the birth hospital. They were invited for a follow-up
visit approximately 14 months later, between February and
March 2009. The recruitment of families has been
described in detail elsewhere [10]. Only primiparous
mothers who were healthy, non-smoking, aged between
20 and 40 years, of Caucasian origin, and had an
uneventful, singleton, full-term pregnancy (37–42 weeks)
were included. The study protocol was approved by the
Ethics Committee of Helsinki University Hospital. All
mothers gave their written informed consent in accordance
with the Declaration of Helsinki. Maternal vitamin D status
was assessed in communal prenatal clinics during the first
trimesters as part of normal follow-up. A second, fasting
blood sample from the mother was collected 2 days
postpartum during the hospital stay between late October
and mid-December 2007. At birth, cord blood was obtained
from the umbilical vein after cord clamping in 81 subjects.
Background data was collected through an extensive
questionnaire. Records on pregnancy follow-up and the
birth report were obtained, including birth weight, length
andheadcircumferencemeasuredbymidwifes,anddurationof
the pregnancy. Birth lengths and weights were transformed into
Z-scores using Finnish sex-specific normative data for fetal
growth [21]. One newborn and her mother were excluded
from the initial analysis due to intrauterine growth retardation.
Eighty-seven (70%) of the original cohort of 124 families
agreedtoparticipateinthefollow-upvisit.Mothersinfamilies
agreed on follow-up tended to be younger (p<0.1), they were
more educated (p=0.09) and had smaller family (p=0.08)
than non-participants, but there were no differences in any
pregnancy outcomes. Before the 14-month visit, the families
received an extensive questionnaire concerning the child’s
health and medical history, sunshine exposure, and use of
vitamin supplements. The questionnaire included a 3-day
food record. During the study visit, one of the researchers
interviewed the family about the child’s development,
including motor and language skills. Of those who agreed
to participate in the follow-up visit, all but three returned the
questionnaire.
Anthropometric measurements were obtained for each
subject. Height was measured at standing position with a
wall-mounted height measuring scale and rounded to the
nearest 0.1 cm. Weight was measured while sitting on a
scale in light clothing and rounded to the nearest 0.1 kg.
Heights were transformed into Z-scores and weights were
expressed as height-adjusted weights according to Finnish
sex-specific normative data for infants [21]. The newborn
bone variables were measured with peripheral computed
tomography (pQCT) from the left tibia. A blood sample
was obtained for laboratory analyses from all but one child.
Local anaesthetical patches (EMLA R; AstraZeneca AB,
Södertälje, Sweden) were used to reduce the discomfort of
venipuncture.
Dietary intakes were calculated from 3-day food records
with Diet32 software (Aivo Oy Finland, Turku, Finland).
884 Osteoporos Int (2011) 22:883–891The nutrient contents of the foods was based on the Finnish
National Food Composition Database, Fineli, version 2001,
maintained by the National Public Health Institute of
Finland, Nutrition Unit. The total intake of vitamin D
included intake from diet and from supplements.
Laboratory measurements
Serum 25-OHD was measured with an OCTEIA immu-
noenzymometric assay (IDS, Bolton, UK). The intra-assay
coefficient of variation (CV) was less than 3.9% and
interassay variation (4.5%). Reproducibility was ensured
by adhering to the Vitamin D External Quality Assessment
Scheme (DEQAS). EIA results were compared with HPLC
results in order to determine the reliability of EIA in
measuring 25-OHD2 concentration. The results were
consistent (r=0.751, p<0.001, R
2=0.495); therefore, the
EIA results were used throughout the study. Vitamin D
status in children was defined as deficient when S-25-OHD
was below 37.5 nmol/l, insufficient when it was between
37.6 and 50 nmol/l, and sufficient when it was above
50 nmol/l, according to the published pediatric reference
values [20]. In adults, a concentration of at least 80 nmol/l is
considered optimal for multiple health outcomes [22].
Serum bone-specific alkaline phosphatase (S-BALP)
was assayed with an OCTEIA Octase BAP immunoenzy-
mometric assay (IDS) in order to characterize bone
formation. Samples were diluted 1:5 to meet the standard
curve. Intra- and interassay CVs were 6.1% and 6.7%,
respectively. The bone resorption marker, serum active
isoform 5b of the tartrate-resistant acid phosphatase (S-
TRACP), was determined with a bone TRAP assay (SBA
Sciences, Turku, Finland). Intra- and interassay CVs were
1.2% and 3.0%, respectively.
pQCT bone measurement
Peripheral bone variables were determined by pQCT from
the left tibia. One 2.5-mm slice (voxel size, 0.4 mm) at the
20% site of distal tibia, was measured with a XCT-2000
scanner (Stratec, Pforzheim, Germany) as described
previously [10]. Data was analyzed using version 5.50 of
the manufacturer’s software package, in which the bone
contour was analyzed with a single threshold of 180 mg/cm
3
for the detection of total bone mineral density (BMD), BMC,
and CSA. The long-term CVs for the phantom BMD and
CSAwere 1.9% and 1.1%, 2.7% and 0.79%, and 0.50% and
0.78% in the total, cortical, and trabecular bone, respectively.
Short-term precision (CV%) was determined with duplicate
measurements of five subjects. CVs for the total bone BMD
and CSA were 6.0% and 6.5%, respectively. On this basis,
the calculated least significant changes for total bone
BMD and CSA were 16.7% and 18.1%, respectively. Out
of all the pQCT measurements at 14 months, 67 (78%)
were successful.
Statistical methods
Statistical analyses were performed with SPSS version 16.0
for Windows (SPSS Inc., Chicago, IL). The two groups
were compared using an independent samples t-test.
Repeated-measures ANOVA was applied to follow 25-
OHD, BMC, CSA, BMD, BALP and TRACP between
baseline and the 14-month visit. These time-points were
compared using contrasts. Determinants for bone analysis
were identified with Pearson correlations. Where necessary,
variables were transformed using logarithms in order to
satisfy statistical assumptions of normality. Differences
between groups in BMC, CSA and BMD at 14 months,
as well as in ΔBMC, ΔCSA and ΔBMD (change from birth
to 14 months), were tested with multivariate analysis
utilizing the same confounding factors. Results are
presented as mean (SD) unless otherwise indicated.
Results were considered significant when p<0.05; p
values between 0.05 and 0.10 were considered trends.
Results
A total of 87 children (57% boys) were followed up for
14 months. Their mean (SD) values for age, weight, height-
adjusted weight, height, and height Z-score were 14.8 (0.5)
months, 10.8 (1.3) kg, 0.68 (7.6)%, 78.6 (3.2) cm, and 0.11
(1.1), respectively. For data analysis, the participants were
divided into two groups based on maternal vitamin D status
during pregnancy. The median maternal S-25-OHD value,
42.6 nmol/l, was used as the cutoff to define two equal-sized
groups of children with below-median (=Low D; mean S-25-
OHD 35.7 [5.0] nmol/l) and above-median (=High D; mean
S-25-OHD 54.9 [9.1] nmol/l) maternal S-25-OHD concentra-
tion. Table 1 presents the background characteristics of these
two groups at baseline and at the 14-month follow-up. The
duration of exclusive was similar in groups (see Table 1).
Eighteen children (21.7%) were still breastfed at the time of
the follow-up visit. Dietary intakes of energy, protein,
vitamin D and calcium did not differ between the groups
and all children had normal development. Only the age when
the children started to walk with support differed between
the groups; all other developmental milestones were similar.
Despite lower vitamin D concentration during pregnancy
and at birth in Low D than in High D (means 35.7 vs.
54.2 nmol/l, and in the cord 40.5 and 59.3 nmol/l,
independent samples t-test; p<0.001, respectively), the 25-
OHD concentrations in the two groups at 14 months were
similar (63 vs. 66 nmol/l, p=0.58). Serum 25-OHD
increased from mean pregnancy value and cord more in
Osteoporos Int (2011) 22:883–891 885Low D than it did in High D (28 vs. 10 nmol/l and 23.6 vs.
6 nmol/l, respectively; independent samples t-test; p<
0.001), although the total intake of vitamin D was similar,
at an average of 12.3 (3.0) μg/day (Table 2). The total
intake of vitamin D correlated positively with 25-OHD
concentration in the whole cohort (r=0.301, p=0.005) and
in High D (r=0.505, p<0.001), but not in Low D (r=0.219,
p=0.168) (Fig. 1). Vitamin D status according to several
reference values [20, 22] did not differ between the groups.
Of the total cohort, 21%, 62% and 17% had S-25-OHD
below 50 nmol/l, between 50 and 79.9 nmol/l or at least
80 nmol/l, respectively (Table 3). Higher dietary intake of
vitamin D and use of D3 supplements were related to
improved vitamin D status.
Tibia BMC, CSA and BMD
Bone measurements were successful in 68 of subjects (78%) at
the14-monthvisit.Forthelongitudinalboneanalysis,complete
baseline and follow-up data were available for 29 subjects in
Low D and 26 subjects in High D. Determinants of bone
variables were gender, birth weight Z-score, walking age,
duration of exclusive breastfeeding and S-25-OHD at
14 months. At the 14-month visit, boys had a higher BMC,
ΔBMC and BMD than girls (independent samples t-test; p=
0.002, p=0.002 and p=0.02, respectively). Birth weight Z-
score correlated strongly with BMC and CSA at 14 months
(r=0.507, p<0.001andr=0.368,p=0.004). Similarly, walking
age was inversely associated with BMC, CSA and S-25-OHD
at 14 months (r=−0.545, p<0.001, r=−0.433, p<0.001, and
r=−0.194, p=0.083, respectively). The duration of exclusive
breastfeeding correlated negatively with BMC, ΔBMC, CSA
and ΔCSA (r varying from −0.377 to −0.428, p=0.002). S-25-
OHD at the 14-month visit was only modestly related to BMD
and ΔBMD (r=−0.230, p=0.08 and r=−0.142, p=0.250), but
was included in the model as well.
The development of BMC from baseline to 14 months
differed between the groups (repeated-measures multivariate
analysis of variance [MANOVA]; p=0.023) (Fig. 2a)d u et o
greater baseline BMC in High D. However, the total BMC
Table 1 Background characteristics and changes in them from baseline value given as mean (SD)
Low D High D Independent samples t-test
N 44 43
Age, months 14.9 (0.5) 14.8 (0.5) 0.336
Males, % 58 55 0.842
a
Anthropometric and growth variables
Weight, kg 10.8 (1.3) 10.8 (1.3) 0.997
Relative weight −1.2 (8.1) 0.2 (6.7) 0.382
ΔWeight, kg 7.1 (1.1) 7.2 (1.0) 0.624
Weight velocity, g/month 475 (72) 488 (67) 0.446
Height, cm 79.0 (2.8) 78.4 (3.5) 0.386
Height Z-score 0.25 (1.0) 0.03 (1.2) 0.378
ΔHeight, cm 27.9 (2.0) 27.7 (2.9) 0.732
Height velocity, cm/month 1.88 (0.12) 1.87 (0.19) 0.951
History of breast feeding and dietary intakes
Duration of exclusive breastfeeding, months 4.2 (1.9) 4.3 (2.0) 0.755
Currently breastfed, N (%) 11 (26.8) 7 (16.6) 0.196
a
Energy intake, kcal/day 920 (220) 930 (180) 0.770
Fat intake, g/day 28.6 (7.9) 28.0 (6.9) 0.698
Protein intake, g/day 43 (13) 42 (10) 0.481
Calcium intake, mg/day 820 (320) 840 (260) 0.863
Total intake of vitamin D, μg/day 12.4 (3.1) 12.2 (2.9) 0.782
Motor and language skills
Age when learnt to crawl, months 8.0 (1.8) 8.2 (1.8) 0.690
Age when learnt to stand, months 8.4 (1.7) 8.5 (1.6) 0.668
Age when learnt to walk with support, months 8.8 (1.6) 10.1 (1.5) 0.001
Age when learnt to walk without support, months 11.9 (1.6) 12.1 (1.5) 0.458
Number of words in use 5.7 (6.2) 6.8 (7.7) 0.490
aPearson chi square
886 Osteoporos Int (2011) 22:883–891gain (ΔBMC=BMC14 month − BMCbaseline) during the first
year was 0.062 (SEM=0.029) g/cm greater in Low D
(MANOVA; p=0.032); consequently, no difference was
observed in BMC between the groups at the 14-month visit.
TB CSA from baseline to the 14-month visit was signifi-
cantly higher in High D than in Low D (repeated MANOVA;
p=0.004) (Fig. 2b) due to the higher baseline CSA in High
D. ΔCSA did not differ between the groups. Thus, a trend to
higher CSA at 14 months by 14.6 (SEM=7.8) mm
2
(MANOVA; p=0.068) remained in High D. There was no
difference between the groups in BMD during the 14 months
(Fig. 2c)o ri nΔBMD. The observed decrease in BMD is a
consequence of a greater increment in CSA compared with
the gain in BMC (69% vs. 18%).
Bone turnover markers
BALP, a surrogate of bone formation, increased dramatically
from baseline (repeated measures MANOVA; p<0.001)
(Fig. 3a), while TRACP concentration remained at the same
level during the 14 months (Fig. 3b). At the 14-month visit,
TRACP, BALP, or their ratio did not differ between the
groups. There was no correlation between BALP and
TRACP, but ΔTRACP correlated positively with Δ25-
OHD (=25-OHD14 month − 25-OHDpregnancy mean)( r=0.345,
p=0.012). Correspondingly, ΔBALP correlated inversely
with Δ25-OHD (r=−0.213, p=0.034).Thecorrelationswere
similar in both groups.
Discussion
This prospective study made three key findings. Firstly, distal
tibia CSA remained larger at 14 months in infants with higher
maternal vitamin D status during pregnancy than in infants
withlowermaternalvitaminDstatus.Secondly,theincrement
in tibial BMC from birth to 14 months was higher in those
withinferiormaternalvitaminDstatusduringpregnancy.This
resulted in similar BMC and BMD at 14 months in both study
groups. Finally, 20% of the children had S-25-OHD below
50 nmol/l at 14 months of age, although their median total
intakeofvitaminDwas12.2(3.0)μg,whichmeetstheNordic
recommendation for this age group [23].
Other interesting findings related to bone growth in this
prospective cohort were that boys had higher BMC, and
BMC increased more during the 14 months and resulted in
higher volumetric BMD in distal tibia than in girls.
Children in high vitamin D group learnt to walk with
support later than children in low vitamin D group,
Fig. 1 Total intake of vitamin D correlated positively with serum 25-
OHD in High D (r=0.505, p<0.001), but not in Low D (r=0.219, p=
0.168). Squares indicate High D and circles indicate Low D
Table 2 Biochemical markers at 14-month visit and changes in them from baseline value given as mean (SD)
Low D High D Independent samples t-test
N 46 40
Mean of first trimester and postpartum maternal 25-OHD, nmol/l 35.7 (5.0) 54.2 (9.1) <0.001
Cord 25-OHD, nmol/l 40.3 (7.2) 59.5 (12.2) <0.001
At 14-month S-25-OHD, nmol/l 63.0 (20.7) 65.6 (21.2) 0.575
S-25-OHD3/total 25-OHD
a 0.50 (0.28) 0.50 (0.24) 0.878
ΔS-25-OHD
b, nmol/l 27.5 (22.2) 10.2 (19.4) 0.001
ΔS-25-OHD
c, nmol/l 23.0 (23.2) 6.0 (22.1) 0.002
S-TRACP, U/l 11.2 (4.0) 10.0 (4.1) 0.199
ΔS-TRACP, U/l −0.28 (4.3) −0.47 (4.7) 0.876
S-BALP,μg/l 124 (38) 122 (38) 0.847
ΔS-BALP, μg/l 69.2 (37.4) 62.4 (42.8) 0.527
aBased on HPLC
bAn increment of S-25-OHD from mean maternal to 14-month visit
cAn increment of S-25-OHD from cord to 14-month visit; N=30, N=31
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consider this as a random finding because it is unlikely that
higher maternal vitamin D status would contribute to this
and several studies have witnessed that vitamin D deficiency
is related to delayed age of walking [24, 25]. In this study,
walking age without support was inversely related to tibia
BMC and CSA, suggesting that earlier walking enhances
bone development. Similarly jumping is shown increase
the outer diameter of the tibia in a randomized controlled
trial of 3- to 5-year-old children [26]. Walking is one of
the first weight-bearing exercises modifying the strength
of the tibia, but it is unsure if the association between
w a l k i n ga g ea n db o n eh e a l t hw ill preserve in the future.
Surprisingly, longer exclusive breastfeeding was linked to
lower bone development, which might be a sum of
prolonged growth rate [27] and possible lower intakes of
nutrients. However, infant 25-OHD at 14-month visit was
only modestly related to bone growth; thus, it was
included as a confounder in the model.
Maternal vitamin D status regulates skeletal growth and
development during fetal life [9, 10, 28]. The present study
proves that these effects partly persist in early childhood, as
has been suggested in a longer prospective study [11]. Tibia
CSA remained somewhat larger in infants whose mothers
had better vitamin D status during pregnancy. Besides
genetic background bone size is affected by various
hormones and it has been shown that growth hormone-
IGF-1 axis is responsible for bone size [29] and periosteal
expansion [30, 31]. Leptin may favor stem cell differentia-
tion towards osteoblasts rather than adipocytes [32]i n
infancy. Furthermore, vitamin D stimulates osteoblasto-
genesis in human mesenchymal stem cells and production
of IGF-1 in osteoblasts [14]. In infants with rickets vitamin
D supplementation increases serum IGF-1 and accelerates
linear growth [33]. In this study, we did not measure IGF-1
and other growth hormone parameters, but height and weight
velocities did not differ between the groups. Although all
infants received vitamin D supplementation, the difference
between the groups in tibia CSA was maintained until
14 months of age. The difference at birth was 16% and 11%
at 14 months. This shows that the fetal bone growth tracks
during the first year [34], which emphasizes the meaning of
maternal nutrition for bone trajectory. Bone size is a major
determinant of bone strength [35] and therefore the observed
differences in CSA may have significant clinical implica-
tions in fracture resistance.
Unlike CSA, BMC or BMD did not differ between the
study groups at the 14-month visit. This is explained by the
steep increment of BMC in Low D group. In fact, the BMC
accrual was about three times higher in Low D than in High
D (28.7% vs. 8.4%), and due to this catch-up in Low D
there was no difference in distal tibia BMC between the
groups at 14 months. The greater increase in BMC in Low
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Fig. 2 BMC, CSA and BMD in study groups from baseline to
14 months. Increase in BMC from baseline to 14 months differed
between the groups (repeated-measures MANOVA; p=0.023) (a) due
to higher baseline BMC in High D. No difference was observed in
BMC between the groups at the 14-month visit. TB CSA from
baseline to 14 months was significantly higher in High D than in Low
D (repeated-measures MANOVA; p=0.004) (b) due to the higher
baseline CSA in High D. At 14 months, CSA remained 14.6 (SEM=
7.8) mm
2 (MANOVA; p=0.068) higher in High D. There was no
difference between the groups in BMD during the 14 months (c)o ri n
ΔBMD. Low D and High D groups are represented by circles and
squares, respectively. Error bars represent SEMs
Table 3 Distribution of vitamin D status in 1-year-old children and
mean intake in each category
S-25-OHD
(nmol/l)
N (%) Total intake of
vitamin D (μg/day)
a
User of D2
(%)
b
<37.5 2 (2.3) 12.2 (4.0) 100
37.6–50 16 (18.6) 10.6 (3.1) 100
50.1–79.9 53 (61.6) 12.4 (2.8) 88.5
≥80 15 (17.4) 13.1 (2.5) 50
Total (N) 86 84 84
aTotal intake differed between categories of 25-OHD (ANOVA; p=0.03)
bDistribution of D2 users differed between categories (chi square; p=
0.001)
888 Osteoporos Int (2011) 22:883–891D group is likely to be due to increased calcium accrual, as
reverted vitamin D status enhances calcium absorption.
Some studies have witnessed that insufficient vitamin D
status during pregnancy is related to lower bone mineral
status in the newborn [9, 10, 28]. Initially, 70% of the
mothers were vitamin D deficient during the pregnancy as
their mean serum 25-OHD for first trimester and 2 days
postpartum was less than 50 nmol/l. Improved postnatal
vitamin D status results in catch-up in BMC, but not in
CSA. Decline in BMD was similar in both study groups
and it reflects a redistribution of bone tissue from the
endocortical to the periosteal surface. An explanation for
declined BMD might be that cortical thickness decreased
during the 14 months while the amount of trabecular bone
increased [36].
In early infancy, peripheral bones grow by increasing the
outer diameter rather than the mineral content [36]. In the
whole group tibia CSA increased dramatically (68%),
indicating that the periosteal diameter and circumference
increased. The growth in periosteal circumference occurred
similarly in groups, but High D group started at a higher
level and hence stayed higher at 14-month visit.
Vitamin D supplementation is recommended for all
infants aged between 2 weeks and 3 years in Nordic
countries in order to guarantee a total intake of 10 μg/day.
All subjects in the present study received supplementation,
compared to a representative study cohort in Finland, in
which 85% of 1-year-old infants and 70% of 2-year-old
infants were reported to receive vitamin D supplementation
[37]. Thus, families in the present study were somewhat
selected and possibly more health-orientated than the
Finnish population in general. In the present study, 85%
of infants had total vitamin D intake that was in line with
the Nordic recommendation [23]. Interestingly, the use of
D3 supplements was associated with improved vitamin D
status to a greater extent than use of D2 supplements, which
is in line with findings of Houghton and Vieth [38].
However, the number of D3 users was very low (N=12),
which means that further comparison between different
forms of vitamin D is not justified. Because of vitamin D
supplementation, S-25-OHD concentration increased during
the follow-up. Interestingly, the increase was higher in group
with inferior S-25-OHD during pregnancy than in group with
higher 25-OHD during pregnancy (ΔS-25-OHD 27.5 vs.
10.2 nmol/l). In line with earlier findings [39, 40], a higher
response was observed in those with initially lower status.
However, neither S-25-OHD nor ΔS-25-OHD was signifi-
cantly associated with pQCT bone variables at 14 months or
their changes during the 14-month follow-up. The study
shows that fetal vitamin D status, rather than postnatal
vitamin D status, affects bone growth during the first year.
On the other hand, S-25-OHD reflects relatively short-term
accumulation of dietary vitamin D and solar exposure [41],
whereas observing differences in bone variables takes more
time. ΔS-25-OHD correlated positively with ΔS-TRACP and
inversely with ΔBALP suggesting that vitamin D affects
bone turnover [42]. Consequently, S-25-OHD may be a
significant determinant of bone turnover in infants, although
growth, diet and motor development also play a part.
There was a positive association between total intake of
vitamin D and 25-OHD in the entire group and in High D,
but not among those infants in Low D whose vitamin D
status during pregnancy was worse. At the 14-month visit,
2.3%, 18.4% and 79.3% were defined as vitamin D
deficient, insufficient and sufficient, respectively [20].
Given that more than 20% of the infants had S-25-OHD
below 50 nmol/L, despite compliance with supplementa-
tion, higher intake of vitamin D is recommended in order to
obtain all the potential health benefits of vitamin D [43,
44]. Optimally, vitamin D sufficiency should be guaranteed
during fetal life as the findings of the present study suggest
that the consequences of poor vitamin D status during the
fetal period cannot be totally reverted by postnatal vitamin
D supplementation.
One of the limitations of the study was that only 70% of
the families were willing to attend the 14-month follow-up
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Fig. 3 Concentrations of BALP and TRACP in study groups from
baseline to 14 months. Low D and High D are represented by circles
and squares, respectively. Error bars represent SEM. BALP increased
from baseline (repeated-measures MANOVA; p<0.001) (a) while
TRACP concentration remained at the same level during the
14 months (b). There were no differences between the study groups
Osteoporos Int (2011) 22:883–891 889visit. Furthermore, only 78% of the pQCT measurements at
14 months were successful, which resulted in problems
with the sample size in data analysis. A sample size of 35
per group would have been required in order to reach
sufficient statistical power. Only total bone parameters were
measured with pQCT from the 20% site of tibia. This site
contains both cortical and trabecular bone, but we did not
quantify those separately because the cortical thickness is
relatively small compared to voxel size and partial volume
effect obscured the results. However, the strength of this
study was a prospective study design with antenatal vitamin
D status.
It can be concluded that postnatal vitamin D supple-
mentation improved vitamin D status in infants and partly
eliminated the differences in bone variables that had
resulted from maternal vitamin D status during the fetal
period. The difference remained in total bone CSA, while it
disappeared in BMC. It seems unlikely, therefore, that
improving vitamin D intake merely in infancy would revert
the consequences of poor vitamin D status during the fetal
period. Based on these observations, additional efforts
should be made to improve vitamin D status during
pregnancy.
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